Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label Study in Healthy Participants Aged 18 to 65 Years to Investigate the CYP3A4 Induction Potential of GSK3882347

NCT05760261 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT05760261
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05760261 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label Study in Healthy Participants Aged 18 to 65 Years to Investigate the CYP3A4 Induction Potential of GSK3882347
Lead sponsor
GlaxoSmithKline
Phase
Phase 1
Overall status
Completed
Start date
April 11, 2023
Completion date
August 20, 2024
Enrollment
27 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

urinary tract infections